Biomarkers, Pharmacological
"Biomarkers, Pharmacological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Measurable biological parameters that serve for drug development, safety and dosing (DRUG MONITORING).
| Descriptor ID |
D054316
|
| MeSH Number(s) |
D23.101.137
|
| Concept/Terms |
Biomarkers, Pharmacological- Biomarkers, Pharmacological
- Pharmacological Biomarkers
- Biological Markers, Pharmacological
- Markers, Pharmacological Biological
- Pharmacological Biological Markers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Pharmacological".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Pharmacological".
This graph shows the total number of publications written about "Biomarkers, Pharmacological" by people in this website by year, and whether "Biomarkers, Pharmacological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 3 | 5 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Pharmacological" by people in Profiles.
-
Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer. 2021 06; 124(12):1970-1977.
-
PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 06; 18(6):345-362.
-
Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial. Pediatr Diabetes. 2019 11; 20(7):871-879.
-
Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):379-386.
-
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):33-39.
-
Treatment response prediction and individualized identification of first-episode drug-na?ve schizophrenia using brain functional connectivity. Mol Psychiatry. 2020 04; 25(4):906-913.
-
Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. J Pediatr Gastroenterol Nutr. 2017 12; 65(6):639-645.
-
Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784.
-
Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jun; 19(6):632-639.
-
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591.